Syneron Medical Ltd. (ELOS)
Lazard Capital Markets 8th Annual Healthcare Conference 2011
November 16, 2011 2:30 PM EST
Asaf Alperovitz – Chief Financial Officer
Thanks for joining us. My name is Marie Thibault. I’m one of the medical technology associates here at Lazard Capital Markets. Up next is Syneron Medical and with us today is Asaf Alperovitz and he’s going to – he’s the Chief Financial Officer of the company and he’s going to give a presentation and right after that we’ll have some time for questions.
So Asaf, why don’t you take it away?
Thank you. Hi everyone. Welcome to Syneron’s presentation. I will start some investment highlights, those of you who are not familiar with Syneron. So what we are is the global leader in aesthetic devices. We control 40% on a worldwide global basis market share and we’re actually growing significantly and outgrowing the market. In the second quarter of this year with 24.1%. In the second quarter which was just released last week we had growth of 28% and we have a strong momentum currently in the marketplace.
What we are, we relate ourselves on the platform of steady company. We have the largest worldwide sales, distribution and service network across 90 countries. We have 11 countries in which we operate directly and in the remaining countries we work with strong distributing partners that are working with us mostly for several years. We have a very comprehensive and diverse product portfolio. We have breadth and depth within our product portfolio and we have leadership position in the largest and fastest growing markets. We’re either number 1 or number 2 with each specific application around the world and I will have a slide specifically presenting that with different applications.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts